pyrroles has been researched along with Adrenocortical Carcinoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Arosio, M; Catalano, R; Elli, FM; Giardino, E; Luconi, M; Mangili, F; Mannelli, M; Mantovani, G; Morelli, V; Peverelli, E; Serban, AL; Spada, A; Treppiedi, D | 1 |
| Chen, Y; Qiu, S; Tu, X; Wang, D; Wu, R; Zhuang, J | 1 |
| Lian, J; Ning, G; Qi, Y; Wang, W; Wang, X; Xu, L; Xu, Y; Zhu, Y | 1 |
| Gelderblom, H; Guchelaar, HJ; Hartigh, Jd; Ploeger, BA; Romijn, JA; van Erp, NP | 1 |
| Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M | 1 |
| Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP | 1 |
| Lin, CI; Moalem, J; Ruan, DT; Whang, EE | 1 |
1 review(s) available for pyrroles and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Indoles; Mitotane; Pyrroles; Sunitinib | 2011 |
2 trial(s) available for pyrroles and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activation; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib | 2011 |
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Disease Progression; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2012 |
4 other study(ies) available for pyrroles and Adrenocortical Carcinoma
| Article | Year |
|---|---|
The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Topics: Actin Cytoskeleton; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Filamins; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin-Like Growth Factor II; Mitogens; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Cells, Cultured | 2021 |
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indoles; Lung Neoplasms; Mitotane; Multiple Pulmonary Nodules; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2015 |
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Mice, Nude; Middle Aged; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2016 |
Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Flavonoids; Humans; Indoles; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2012 |